We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
101
Cabaletta Bio
CABA
$531M
$702K ﹤0.01%
662,063
– –
CYPH
102
Cypherpunk Technologies Inc
CYPH
$153M
$644K ﹤0.01%
55,971
– –
FHTX icon
103
Foghorn Therapeutics
FHTX
$420M
$612K ﹤0.01%
45,027
– –
BNR
104
Burning Rock Biotech
BNR
$103M
$609K ﹤0.01%
20,913
– –
TARA icon
105
Protara Therapeutics
TARA
$228M
$585K ﹤0.01%
199,671
– –
KZR
106
DELISTED
Kezar Life Sciences
KZR
$512K ﹤0.01%
6,195
-7,773
-56% -$686K
INZY
107
DELISTED
Inozyme Pharma
INZY
$510K ﹤0.01%
106,999
– –
SERA icon
108
Sera Prognostics
SERA
$84.4M
$331K ﹤0.01%
201,562
– –
VINC
109
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$319K ﹤0.01%
12,069
– –
BLCM
110
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$296K ﹤0.01%
249,123
– –
PASG icon
111
Passage Bio
PASG
$14.3M
$276K ﹤0.01%
5,858
– –
SRZNW
112
DELISTED
Surrozen Inc Warrant
SRZNW
$159K ﹤0.01%
833,333
– –
LOGC
113
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$158K ﹤0.01%
451,478
– –
NEXI
114
DELISTED
NexImmune, Inc. Common Stock
NEXI
$32K ﹤0.01%
800
-10,965
-93% -$679K
AXSM icon
115
Axsome Therapeutics
AXSM
$10.9B
– –
-610,970
Closed -$25.3M
KURA icon
116
Kura Oncology
KURA
$1.06B
– –
-274,458
Closed -$4.41M
NBIX icon
117
Neurocrine Biosciences
NBIX
$15.5B
– –
-676,975
Closed -$63.5M
NVAX icon
118
Novavax
NVAX
$1.47B
– –
-48,168
Closed -$3.55M
SRPT icon
119
Sarepta Therapeutics
SRPT
$1.98B
– –
-123,456
Closed -$9.64M
OYST
120
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
– –
-61,424
Closed -$715K
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2022 Portfolio in Review

As of Q2 2022, Julian Baker held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Julian Baker added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Julian Baker's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Julian Baker fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Julian Baker's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Julian Baker opened 5 new positions and closed 6 in Q2 2022.
  • Julian Baker's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.